|
Thank you everyone. My status is getting down to fewer choices which is somewhat daunting.
Maggie, A donor leukocyte infusion (DLI) (which I will receive from my German donor) is a possible strategy for managing a patient in relapse. In this procedure, the patient receives a boost of immune cells from the original donor's blood. In certain circumstances, it may be extremely effective in controlling recurrent cancer in a patient. This ability of the donor cells to control or eliminate the residual malignant cells has been called the graft-versus-tumour effect. Their are drawbacks however with a DLI primarily GVHD which is unpredictable. The success rate for the DLI is about 15-20 percent. If it fails the situation will be difficult.
__________________
age 70, dx RAEB-2 on 11-26-2013 w/11% blasts. 8 cycles Vidaza 3w/Revlimid. SCT 8/15/2014, relapsed@Day+210 (AML). Now(SCT-Day+1005). Prepping w/ 10 days Dacogen for DLI on 6/9/2017.
|